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Abstract: Endothelial cells (ECs) constitute the innermost layer that lines all blood vessels from the
larger arteries and veins to the smallest capillaries, including the lymphatic vessels. Despite the
histological classification of endothelium of a simple epithelium and its homogeneous morphological
appearance throughout the vascular system, ECs, instead, are extremely heterogeneous both
structurally and functionally. The different arrangement of cell junctions between ECs and the local
organization of the basal membrane generate different type of endothelium with different permeability
features and functions. Continuous, fenestrated and discontinuous endothelia are distributed based
on the specific function carried out by the organs. It is thought that a large number ECs functions and
their responses to extracellular cues depend on changes in intracellular concentrations of calcium ion
([Ca2+]i). The extremely complex calcium machinery includes plasma membrane bound channels
as well as intracellular receptors distributed in distinct cytosolic compartments that act jointly to
maintain a physiological [Ca2+]i, which is crucial for triggering many cellular mechanisms. Here,
we first survey the overall notions related to intracellular Ca2+ mobilization and later highlight the
involvement of this second messenger in crucial ECs functions with the aim at stimulating further
investigation that link Ca2+ mobilization to ECs in health and disease.
Keywords: angiogenesis; endothelial cells; endothelial dysfunction; calcium; NAADP; NO;
second messengers
1. Introduction
By a histological view, the endothelium is classified as a covering simple (monolayer) squamous
epithelial tissue that lines the inner surface of the entire vascular tree from the heart to the smallest
capillary, including the lymphatic vessels. Therefore, both vascular and lymphatic endothelial cells
(ECs) are in direct contact with the lymph, the blood tissue and a variety of circulating cells. Although
the vascular endothelium preserves its typical histological characteristics along most of the entire
vascular system, ECs instead, display significant heterogeneity and differentiation mostly ascribable
to the local environment found in different organs. Distinguishing morphological changes of ECs
that display prominent cuboidal appearance are found, for instance, in high endothelial venules
defined as specialized postcapillary venules found in lymphoid tissues that support high levels of
lymphocyte migration from the blood [1]. In addition, the occurrence of a continuous, fenestrated
and discontinuous endothelium, with distinct permeability features, is widely found throughout the
body [2]. EC heterogeneity also takes account of distinct endocytic pathways, expression of specific
intercellular junctions and the local composition of the endothelial surface layer [3–5], a 500-nm
macromolecular coating of glycosaminoglycans of the apical surface of ECs that physically interacts
with circulating blood cells. Despite their heterogeneity, ECs all share common functions, including
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the maintenance of homeostatic functions, the regulation of the blood flow, the inhibition of the
coagulation cascade, the exchange of molecules between the blood and tissues and the modulation
of the inflammatory response [6]. To accomplish these functions, ECs must operate as accurate
sensors able to distinguish and handle a variety of extracellular cues in order to generate appropriate
responses that guarantee the physiological condition in vivo [7]. Therefore, the precise differentiation
of ECs and their functional status are fundamental for organ homeostasis and become crucial in
pathological conditions affecting the cardiovascular system. Calcium ion (Ca2+) is a ubiquitous second
messenger that contributes to regulate a variety of cellular processes in many electrically excitable and
non-excitable cells including ECs [8]. The control of Ca2+ signaling in different EC types has engaged
a great interest since a long time [9]. To this regard, these authors have discussed Ca2+ metabolism
in ECs and, in addition, raised the crucial point about EC heterogeneity in the regulation of Ca2+
signaling that is still debated and currently under investigation. Many crucial vascular functions,
such as the control of vascular tone and the secretion of vasoactive factors, are associated to specific
fluctuation of intracellular calcium concentrations [Ca2+]i. As it occurs in many cell types most of
the intracellular (Ca2+) in ECs is sequestered in the endoplasmic reticulum (ER) [9], while the role
of mitochondria in calcium storage in this cell type is modest [10–12]. It has been estimated that in
ECs about three quarters of the entire Ca2+ pool is sequestered into ER, while the remaining 25%
constitutes the mitochondrial pool [10]. However, it is generally accepted that there is an overall
cooperation between ER and mitochondria in the regulation of intracellular Ca2+ flux. Indeed, in many
cell types, mitochondria typically function by sequestering cytosolic Ca2+ that is later recaptured by
ER. Unfortunately, mitochondria are efficient makers of reactive oxygen species (ROS) such as the
superoxide anion (O2−), hydrogen peroxide (H2O2) and hydroxyl radical (OH) all potentially dangerous
for the host cell as well as involved in a multitudinous of physiological cellular functions [11–13].
Since ROS generate biochemically as by-products during mitochondrial electron transport, cells have
developed a number of defense mechanisms aiming at preventing the oxidative stress. On the other
hand, ROS also act as potent signalling agents that promote specific cellular mechanisms such as
proliferation and differentiation [14–16]. Of note, a number of recent studies suggested that ROS
production and Ca2+-dependent signals are two intimately integrated mechanisms that actively
interplay. Indeed, it has been suggested that high concentration of mitochondrial Ca2+ stimulates
ROS production while the regulation of Ca2+ signal can be redox-dependent [17–19]. Unfortunately,
the exact molecular mechanisms that regulate the crosstalk between calcium and ROS signaling in ECs
remain elusive. Furthermore, during the last decade, a number of intracellular acidic compartments
have been proposed to serve as intracellular Ca2+ stores in many cell types [20]. These include a
variety of endo-lysosome-like organelles equipped with the recent discovered Ca2+-permeable channels
through which nicotinic acid-adenine dinucleotide phosphate (NAADP) mobilizes Ca2+ (see below).
In addition, contributing to make the scenario even more complex there is the presence of a variety
of intracellular heterogeneous calcium binding proteins (CBP) that specifically bind Ca2+ and finely
regulate its cytosolic concentration [21]. Among these, some members of the S100 CBP family have
called high interest in ECs for their contribution to regulate crucial mechanisms such as the control of
cell cycle and senescence and more in general for their potential role in vascular functions [22–24].
1.1. Generation of Intracellular Second Messengers
The term second messenger refers to a variety of small and diffusible molecules that convey and
amplify primary signals originating from the cell-surface receptors to intracellular effector proteins [25].
The major classes of second messengers released upon extracellular (primary) stimuli include cyclic
nucleotides (such as cAMP and cGMP), inositol 1, 4, 5-triphosphate (IP3), diacylglycerol (DAG)
and Ca2+ [25]. In addition, cell expressing ADP-ribosyl cyclases also synthetize cyclic ADP-ribose
(cADPR) and NAADP from NAD and NADP, respectively [26]. Both cADPR and NAADP are two
well-known Ca2+ mobilizing agent in many cell types, whose production involve distinct intracellular
compartments [27,28]. More recent studies have reported the existence of a NAADP-synthesizing
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CD38 restricted to lysosomes/endolysosomal compartments of both human and mouse cells [29,30].
Ca2+ represents one of the most studied and ubiquitous second messengers that regulates a variety
of intracellular events in many cell types, including ECs. The amount of cytosolic Ca2+, which is
kept at a very low concentration (≤ 10−7 M) in resting cells, can either increase due to the influx from
the extracellular space through specific calcium channels expressed on the cell surface or by release
from intracellular stores such as ER (or sarcoplasmic reticulum in muscle cells). Ca2+ mobilization
from intracellular stores typically occurs after the recruitment of either phospholipase C (PLC) β by G
protein-coupled receptors (GPCRs) or PLC-γ isoforms by tyrosine kinase receptors and nonreceptor
tyrosine kinases that induce the hydrolysis of the phospholipid phosphatidylinositol-4,5-bisphosphate
(PIP2) to generate IP3 and DAG. While DAG remains close to the plasma membrane where it
activates protein kinase C (PKC) [31,32], IP3 diffuses through the cytosol and binds to IP3 receptors
(IP3Rs) expressed on ER membrane causing the increase in [Ca2+]i [33]. Likewise, different types
of Ca2+-selective intracellular channels termed ryanodine receptors (RyRs) trigger the release of
Ca2+ from the sarcoplasmic reticulum (ER) in muscle cells [34]. Once released from intracellular
stores, diffusible Ca2+ can either bind to several Ca2+-binding targets or it can recruit downstream
effector proteins [35] that in turns drive a plethora of downstream mechanisms leading to contraction
of muscle cells, cell adhesion, cell cycle progression, cell growth, cell motility, cell differentiation,
fertilization and cell death. Moreover, although ER and its specialized form in muscle cells are by far
considered the best characterized intracellular calcium store in both non-excitable and excitable cells,
othercompartments displaying an acidic milieu have been reported to serve as a calcium depository in
different cell types [20,36]. To date, among the most recent and potent calcium-mobilizing intracellular
messengers from acidic compartments is the nicotinic acid-adenine dinucleotide phosphate (NAADP),
whose function was first discovered in sea urchin eggs [37,38]. Ca2+ release from intracellular acidic
compartments has been more recently linked to a novel class of membrane bound TPC expressed on
lysosome-like organelles [39–41]. To date, three distinct TPCs termed TPC1, TPC2 and TPC3 (not present
in humans [42]), have been identified within different types of intracellular acidic compartments like
lysosomes and endosomes. Interestingly, the presence of functional NAADP-sensitive lysosome-like
acidic compartments has been established in aortic ECs and it has been linked to nitric oxide
(NO) synthesis and muscle relaxation [43]. In addition, in ECs, NAADP has been also found to
contribute to crucial mechanisms such as histamine-induced release of von Willebrand factor [44]
and VEGFR2-mediated signaling and neoangiogenesis [45,46], further supporting the role of TPCs as
specific NAADP receptors expressed by lysosome-like organelles. Of note, it has been demonstrated
that the flavonoid naringenin, by acting on human TPC2 channel activity, dampens NAADP-dependent
intracellular Ca2+ responses to VEGF in ECs and impairs angiogenic activity in VEGF-containing
matrigel plugs implanted in mice [47,48]. A recent study also linked TPC1 and NAADP-induced Ca2+
mobilization to the proliferation of metastatic colorectal cancer cells, suggesting that NAADP-induced
signaling through TPC1 may represent an interesting mechanism to develop potential clinical targets in
patients [49]. Whatever is the mechanism that led to the increase in cytosolic [Ca2+]i and once specific
downstream events have been activated, the amount of cytosolic Ca2+ rapidly decreases, bringing
back the cell at its resting state. To this regard, both plasma membrane Ca2+ ATPases and sodium
calcium exchangers came into play to extrude Ca2+ back into the extracellular space [50,51]. At the
same time, the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) causes cytosolic Ca2+ storage into
ER, re-establishing physiological cytosolic [Ca2+]i. Therefore, one may expect that any condition that
interferes with the complex molecular machinery heading the series of event occurring during Ca2+
mobilization may affect normal behavior of ECs, leading to pathological conditions [52].
1.2. Calcium Machinery and Ca2+ Measurement
A multiplicity of vascular functions relies by the integrity of the endothelial layer lining the intima
of blood vessels. Although ECs are non-excitable cells, changes in [Ca2+]i which generate in response
to disparate extracellular cues are crucial regulators of a number of vascular mechanisms linked to
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regulation of the vessel tone, inflammation, coagulation and regulation of vascular permeability, just to
mention a few. A variety of ion channels expressed the cell surface of ECs mediate Ca2+ influx from the
extracellular milieu that could be followed by intracellular Ca2+mobilization from internal stores. These
include Voltage-Dependent Calcium Channels [53], Transient Receptor Potential Channels (TRP) [54,55],
ORAI Family of Calcium Channels and Store-Operated Calcium Channels (SOC) [56–58]. The extensive
functional and structural heterogeneity of the plasma membrane calcium channels has been largely
reviewed [57,59,60]. In addition, some of these channels have been linked to vascular dysfunctions [61].
Although the amplitude and the duration of Ca2+ increase dependent on the type of stimulus and
the vessel type, changes in [Ca2+]i can be monitored in living cells. To measure in-cell changes in
cytosolic [Ca2+]i or agonist-induced Ca2+ mobilization, a number of fluorescent Ca2+ indicators are
commercially available. These indicators have been first developed during the early 80′s and have
soon became a fundamental tool for monitoring intracellular Ca2+ changes in many cell types [62–64].
Among these, ratiometric Ca2+ indicators such as Fura-2-acetoxymethyl ester (Fura-2 AM) is a widely
used membrane-permeable indicator that once inside the cell is subjected to an enzymatic cleavage that
removes the acetoxymethyl group allowing it to bind to free Ca2+. At this point, 340/380 nm excitation
ratio of the molecules allows an accurate measurement of the intracellular Ca2+ concentration. Hovever,
prevailing cell culture approaches may introduce modifications in morphology as well as expression
and topography of ion channel of ECs in a way that could confound comparison to physiological
conditions observed ex vivo or in vivo. Given the complexity of endothelial Ca2+ signaling, a major
challenge is to clarify the spatial and temporal dynamics of Ca2+ mobilization in intact tissues [65,66].
To this end, the dynamic of the Ca2+ signals and its physiological implications have been investigated
by a novel approach using intact endothelium from arteries [65,67–69]. Interestingly, to elucidate these
dynamics events, Taylor and co-workersdeveloped a novel algorithmic process to evaluate basal Ca2+
signals within the endothelium of intact mouse mesenteric arteries [70].
1.3. Physiological Calcium Signaling in ECs
Despite its histological classification of an epithelial tissue and based on the numerous molecules
such as vasoactive compounds, growth factors, cytokines and coagulation factors released by ECs,
the endothelium is considered a genuine endocrine organ [71]. The endocrine feature of the endothelium
adds to its well-known role of serving as a histological barrier separating the blood from the connective
tissue underneath. This physical role turns into a more sophisticated as well as clinically relevant
structure in specific areas of the body as it occurs in the blood–brain-barrier or the blood–thymus
barrier [72–74]. However, taking into consideration the many functions played by the vascular
endothelium, the capability of ECs to respond to extracellular stimuli such as neurotransmitters,
growth factors and hormones is crucial in the regulation of the vascular tone. Notably, the secretion
of a variety of vasoactive compounds, such as NO [75] and prostaglandin I2 (PGI2) by ECs relies on
the capability of these cells to finely regulate [Ca2+]i [76–78]. NO [75] is a soluble gas with a half-life
of only few seconds synthesized by NO synthase (NOS) enzyme expressed in a variety of cell types,
including red blood cells, platelets and ECs [79–81]. The activity of NOS enzymes depends on the
presence of calmodulin [82], a cytosolic Ca2+-binding protein widely expressed in many eukaryotic
cells. The talent of NO to induce Ca2+ mobilization from intracellular compartments, particularly
ER, has been first described in ECs [83] and more recently it has been reported to involve ryanodine
receptors [84]. Despite its short half-life, NO induces both short- and long-lasting effects in target
cells by inducing at least three different waves of gene expression [85]. The well-known effect of
NO generated by the endothelial NOS (eNOS) refers to its ability to relax vascular smooth muscle
cells (VSMC) by increasing the activity of cytosolic cyclic guanosine monophosphate (cGMP) that
induces Ca2+ uptake into intracellular stores and inhibits calcium–calmodulin myosin light chain
kinase-complex formation. Indeed, although NO may count on different intracellular target, most
of NO-dependent effects rely on the activation of the cGMP [86]. In addition, eNOS activity per se is
regulated by a variety of proteins that act by either increasing or reducing its enzymatic activity [87].
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Among proteins that behaves as a negative regulators of eNOS, there is caveolin-1 (cav-1) [88,89],
the scaffolding protein of flask-shaped caveolae particularly enriched in the plasma membrane of ECs.
Since caveolae have been involved in the regulation of intracellular Ca2+ levels in ECs and other cell
types, it is not surprising that the perturbation of the caveolar network or the abnormal expression
of cav-1 may results in the perturbation of eNOS activity and NO release from ECs. Considering
the variety of vascular functions that depend by the bioavailability of NO, pathological conditions
that affect eNOS activity may result in endothelial dysfunctions and cardiovascular diseases. These
pathological conditions turn eNOS to a superoxide anion (O2−) producing enzyme instead of NO which
contributes to cell injury and vascular diseases, a mechanism known as eNOS uncoupling [90]. Due to
the reliance of eNOS from intracellular Ca2+ and the role that NO plays in blood pressure homeostasis,
it is expected that several calcium channel blockers, or calcium antagonist, are employed to treat
hypertension, although the precise mechanisms influenced by these drugs need more investigations.
Among the variety of agonists stimulating intracellular Ca2+ mobilization in ECs already
mentioned above, it has been demonstrated that histamine through its H1 receptor and VEGF/VEGFR2
pathway play a relevant physiological role in the regulation of vWF release, capillary-like formation
and in vivo angiogenesis, respectively [44,45]. Supporting these studies, Vinet et al., demonstrated
that bradykinin and histamine induced calcium increase in ECs by means of different intracellular
mechanisms based on the different sensitivity to thapsigargin. These authors claimed that bradykinin-
and histamine-induced intracellular Ca2+ increase are of physiological relevance in modulating
adrenal gland microcirculation [91]. The physiological role of a number of agonist-induced Ca2+
mobilization in ECs, such as angiotensin II, serotonin and acetylcholine has previously been extensively
reviewed [8,92]. Their role has been demonstrated in activating phospholipase C-β1 followed by the
generation of IP3 and DAG. On the other hand, growth factors such as platelet-derived growth factor
and epidermal growth factor coupled to tyrosine kinase receptors activate phospholipase C-γ1 and
elicit Ca2+ mobilization [8,92].
1.4. Role of Ca2+ in EC Permeability and Inflammatory Response
The endothelium serves as a crucial semipermeable barrier between blood and the interstitium.
However, the inflammatory status induces changes in the permeability of this barrier, allowing access
of plasma proteins to the surrounding tissues supporting vascular leaking. The regulation of vascular
permeability is a hallmark of inflammation and is mediated by numerous inflammatory mediators such
as histamine and thrombin. The ability of these molecules to induce intracellular Ca2+ mobilization
has been widely demonstrated both in mast cells and ECs [93–95]. Nevertheless, VEGF, a major
player able to activate the angiogenic pathway in ECs has been directly involved in the regulation
of cell permeability via a Ca2+-dependent pathway [96]. In addition, we recently suggested that
histamine-mediated release of von Willebrand factor (vWF) through H1 receptor from acidic stores
requires the presence of functional NAADP receptors in ECs. Yet, under the same experimental
condition, thrombin-induced vWF secretion was unaffected, demonstrating the obligatory role of
NAADP exclusively in H1R-induced cell responses [44]. Due to the crucial role that vWF plays in
the regulation of hemostatic functions, we proposed that targeting NAADP signaling in ECs may be
beneficial to set in novel clinical strategies to counteract vascular diseases. ECs also play a crucial
role in inflammation by responding to proinflammatory stimuli such as lipopolysaccharide (LPS),
interleukin (IL)-1α and tumor necrosis factor (TNF). TNF exerts its function by binding to TNF receptor
1 and 2 that are differently distributed in ECs [97,98]. A soluble form of both receptors (sTNFR1 and
sTNFR2) that are produced by shedding of the membrane bound molecules has been also described in
ECs [99,100]. Although the functional significance of sTNFRs requires more investigation, sTNFR1 may
function as a decoy receptor for TNF, thus reducing its proinflammatory functions [98]. Interestingly,
while TNFR1 compartmentalization into lipid rafts/caveolae only partially affects TNF signaling in
ECs [101,102], the presence of a functional caveolar network is critical for histamine-induced release of
sTNFR1. By contrast, H1R-induced intracellular Ca2+ mobilization appears to be independent of the
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presence of functional lipid rafts [100], suggesting that the two mechanisms proceed independently
each other. In Human Umbilical Vein Endothelial Cells (HUVEC), the release of s TNFR1 is strictly
dependent on the expression of an integral membrane aminopeptidase, also known as ARTS-1 that
associates with the calcium dependent protein nucleobindin-2, promoting TNFR1 release into the
extracellular milieu via exosome vesicles [103]. Since the release of soluble TNFR1 is of primary
importance to regulate TNF-induced signaling, these findings indicate that the precise regulation of
[Ca2+]i contributes to modulate the inflammatory response of ECs. In addition, more recent studies in
humans suggested that EC functions are affected by elevated circulating calcium levels that, indeed,
must be finely regulated in physiological conditions in vivo. Several studies indicate a direct correlation
between blood calcium level and the onset of cardiovascular diseases and atherosclerosis [104,105].
ECs play a crucial role in the early step of atherosclerosis by inducing upregulation of adhesion
molecules such as vascular cell adhesion molecule (VCAM-1) that triggers the recruitment of circulating
monocytes [106,107] in response to inflammatory cytokines such as TNF [108]. Due to their specific
position in the vascular system, ECs can serve as a sensor of extracellular Ca2+ level and any increase
of the ion in the bloodstream will increase [Ca2+]i, which is fundamental to upregulate the expression
of endothelial adhesion molecules [109,110]. These findings suggest a direct role of ECs in balancing
both circulating and intracellular Ca2+ levels, which is crucial to regulate the inflammatory response
and the onset of cardiovascular diseases.
1.5. Calcium Signaling in Normal and Pathological Angiogenesis
New blood vessel formation or angiogenesis not only represents a crucial mechanism in which
ECs are the principal players, but plays a critical role during tumor growth and metastatic spread.
Tumor cells obtain oxygen and nutrients by inducing the formation of new blood vessels from the local
vasculature, giving rise to new vascular sprouting that can grow toward and infiltrate into the tumor
mass sustaining its persistence and progression. As the tumor increases in size, nutrient deprivation and
the resulting tumor hypoxia induce the release of soluble factors that "switch" ECs from a quiescent to
an active status, an essential step that triggers new blood vessels formation [111,112]. A great variety of
molecules have been identified that serve as angiogenic activators. These include VEGF, basic fibroblast
growth factor (bFGF), angiogenin, transforming growth factor (TGF)-α, TGF-β, tumor necrosis factor
(TNF)-α, platelet-derived endothelial growth factor, granulocyte colony-stimulating factor, placental
growth factor, interleukin-8, hepatocyte growth factor and epidermal growth factor [113], whose
release is also stimulated by the tumor microenvironment itself. Tumor-derived VEGF attracts and
stimulates ECs to produce metalloproteinases (MMPs) that weaken the extracellular matrix facilitating
the migration of ECs into the surrounding tissue. Under these circumstances ECs redeploy themselves,
giving rise to hollow tubes that further evolve into a mature network of new blood vessels [114,115].
Finally, the intervention of pericytes and mural cells, i.e., vascular smooth muscle cells, contributes
to the final stabilization of the newly formed blood vessels [116]. It has been demonstrated that
the maintenance of Ca2+ signaling is necessary for both tube formation in vitro and angiogenesis
in vivo [117]. Moreover, studies carried out by either overexpressing a dominant negative of TRPC6
on microvascular ECs or by its pharmacological inhibition in HUVEC, demonstrated the obligatory
contribution of this channel to VEGF-mediated increase of intracellular Ca2+ as well as for the activation
of VEGF-induced proliferation and angiogenesis [118,119]. In addition, cancer cells can mimic ECs in
the formation of tubular-like structures, a phenomenon known as vasculogenic mimicry (VM) [120,121]
observed in many cancers. To this regard, VE-cadherin, Notch and hypoxia-inducible factor 1-α
(HIF1-α) are thought to be the most relevant signaling molecules involved in VM [122]. More recently,
it has been reported that both intracellular and extracellular Ca2+ levels along with the involvement of
ανβ3 and ανβ5 integrins play a crucial role during the development of capillary-like structures in
melanoma [123]. Another study carried out on different cancer cell lines including human fibrosarcoma,
breast adenocarcinoma and skin melanoma demonstrated the contribution of integrin β1 in the
formation of VM-like structures. In particular, the administration of EGTA, a Ca2+ chelator, inhibited
the formation of VM-like network, a phenomenon that was rescued by the addition of CaCl2 [124].
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2. Conclusions
Undoubtedly the growing number of studies on Ca2+ signaling has greatly improved our
knowledge about the control of fundamental mechanisms that occur in ECs. Although the crucial
role of Ca2+ in VEGF-mediated signaling in ECs has been widely reported, understanding of the
precise molecular mechanisms through which variation of the [Ca2+]i controls the equilibrium between
pro- and antiangiogenic factors remains crucial to the comprehension of the dysfunctions of the
vascular endothelium. We believe that the use of genetic targeting of critical molecules involved in
Ca2+signaling and the further characterization of the mechanisms controlling Ca2+ mobilization from
intracellular stores in ECs is crucial to develop clinical strategies to counteract vascular dysfunctions
that may lead to severe cardiovascular diseases. Moreover, although the effects of Ca2+ antagonists in
ECs remain quite controversial, deepening the molecular mechanisms activated by these drugs could
improve our knowledge of how Ca2+ signals originating from ECs contribute to ameliorate vascular
dysfunctions, thereby reducing the risk of severe cardiovascular diseases such as atherosclerosis,
hypertension, stroke and peripheral arterial disease. Notably, the expression of low voltage activated
T-type Ca2+channels and their involvement in the reduction of vascular dysfunctions [53,125] raised
great interest in the use of specific Ca2+antagonists in ECs. However, their specific activity within
the vascular bed remain still unclear and need further investigation. Though we did not address this
topic in this work, it has been also reported the higher sensitivity as well as an increased intracellular
Ca2+ levels in endothelial progenitor cells compared to the adult ECs [126,127]. The discovery that
endothelial colony forming cells isolated from different sources, i.e., peripheral vs. umbilical cord
blood, exhibit different arrangement of Ca2+ channels and different angiogenic capabilities should
encourage further investigation aiming at linking Ca2+ signaling to revascularization. In conclusion,
the main purpose of this review is to focus the reader’s attention on the calcium machinery in EC
functions and to stimulate further investigation that may contribute to develop novel clinical strategies
helpful in the field of vascular diseases.
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